[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587698":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":16,"responsibleParty":106,"collaborators":108,"id":111,"slug":112,"hasResults":113,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":113,"sex":118,"minAge":119,"maxAge":7,"enrollmentInfo":120,"targetDuration":7,"studyType":123,"phases":7,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":19,"whyStopped":7,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},{"fullName":5,"class":6},"The Netherlands Cancer Institute","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Pien Debets, Study coordinator","CONTACT","0205129111","p.debets@nki.nl",{"name":15,"role":11,"phone":7,"phoneExt":7,"email":7},"Ingrid Mandjes, Clinical Projects Manager",[17,36,45,54,67,80,94],{"facility":18,"status":19,"city":20,"state":21,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Medical spectrum Twente","RECRUITING","Enschede","Overijssel","7500 KA","Netherlands","NL",{"type":26,"coordinates":27},"Point",[28,29],6.89583,52.21833,{"lat":29,"lon":28},[32,34],{"name":33,"role":11,"phone":7,"phoneExt":7,"email":7},"M Wymenga, MD",{"name":33,"role":35,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"facility":37,"status":38,"city":39,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":40,"geoPoint":44,"contacts":7},"Amsterdam University Medical Center","NOT_YET_RECRUITING","Amsterdam",{"type":26,"coordinates":41},[42,43],4.88969,52.37403,{"lat":43,"lon":42},{"facility":5,"status":19,"city":39,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":46,"geoPoint":48,"contacts":49},{"type":26,"coordinates":47},[42,43],{"lat":43,"lon":42},[50],{"name":51,"role":11,"phone":52,"phoneExt":7,"email":53},"Sabine Linn, Prof","+3125129111","s.linn@nki.nl",{"facility":55,"status":38,"city":56,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Amphia","Breda",{"type":26,"coordinates":58},[59,60],4.77596,51.58656,{"lat":60,"lon":59},[63,66],{"name":64,"role":11,"phone":7,"phoneExt":7,"email":65},"J B Heijns, MD","JHeijns@amphia.nl",{"name":64,"role":35,"phone":7,"phoneExt":7,"email":7},{"facility":68,"status":19,"city":69,"state":7,"zip":70,"country":23,"countryCode":24,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"UMCG","Groningen","9713 GZ",{"type":26,"coordinates":72},[73,74],6.56667,53.21917,{"lat":74,"lon":73},[77,79],{"name":78,"role":11,"phone":7,"phoneExt":7,"email":7},"J Nuver, MD",{"name":78,"role":35,"phone":7,"phoneExt":7,"email":7},{"facility":81,"status":19,"city":82,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Maastricht University Medical Center","Maastricht",{"type":26,"coordinates":84},[85,86],5.68889,50.84833,{"lat":86,"lon":85},[89,92],{"name":90,"role":11,"phone":7,"phoneExt":7,"email":91},"V Tjan-Heijnen, MD","a.jager@erasmusmc.nl",{"name":93,"role":35,"phone":7,"phoneExt":7,"email":7},"V Tjan-Heijnen, Prof. MD",{"facility":95,"status":19,"city":96,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"ErasmusMC","Rotterdam",{"type":26,"coordinates":98},[99,100],4.47917,51.9225,{"lat":100,"lon":99},[103,105],{"name":104,"role":11,"phone":7,"phoneExt":7,"email":91},"Agnes Jager, Prof. MD",{"name":104,"role":35,"phone":7,"phoneExt":7,"email":7},{"type":107,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[109],{"name":110,"class":6},"Dutch Cancer Society","100587698","tao-towards-optimal-neoadjuvant-systemic-therapy-of-stage-iii-triple-negative-breast-cancer-100587698",false,"NCT06931769","TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer","TAO","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* Histologically confirmed adenocarcinoma of the breast\n* Assumed clinical or pathological stage III (TNM) breast cancer\n* Breast tumor must be:\n\n  * HER2-negative: i.e. either score 0 or 1 at immunohistochemistry or score 2 at immunohistochemistry and negative at in situ hybridization (ISH, CISH or FISH)\n  * Hormone receptor negative i.e. an estrogen receptor (ER) of \\\u003C10% and progesterone receptor (PR) of \\\u003C10%.; or in case of a histological grade III tumor an ER of \\\u003C50% and a PR of \\\u003C50%.\n* Patients are planned to receive the complete standard of care in the Netherlands; neo-adjuvant chemotherapy according to local practise\n* Participating patients have to be able to use a mobile phone, tablet, laptop and\u002For computer and understand the Dutch language\n\nExclusion Criteria:\n\n* Evidence of distant metastases. Staging examinations should have been performed according to Dutch national guidelines.\n* Patients who are only treated systemically in the adjuvant setting\n* Participation in another clinical study with an treatment intervention during the course of this study.","ALL","18 Years",{"count":121,"type":122},100,"ESTIMATED","OBSERVATIONAL","This prospective, national, multi-centre study will include patients with stage III triple-negative breast cancer (TNBC) who are planned to start with standard (neo)adjuvant systemic treatment. The study will gather clinico-pathological, treatment and follow-up information of participating patients through Dutch databases. Participating patients will be asked to complete cancer specific and more generic quality of life questionnaires at nine time points during and after their anticancer treatment in a mobile application.\n\nFor all patients who have consented to additional blood collection, to assess the course of dynamic ctDNA during (neo)adjuvant chemotherapy and its relation with outcome, two tubes will be collected at four different time points.",[126],"Breast Cancer",[128,129,130,131],"Stage III","Triple Negative","Neo adjuvant treatment","Quality of Life","2026-05-11",{"date":134,"type":135},"2026-05-13","ACTUAL",{"date":137,"type":135},"2025-11-06",{"date":139,"type":122},"2030-07-01",{"name":5,"class":6},7]